Huasun(SZ:000790) Zheng Quan Zhi Xing·2025-08-21 16:48Core Viewpoint - Chengdu Huashen Technology Group Co., Ltd. plans to publicly transfer 51% equity of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., with an initial valuation of 63.7806 million RMB [1][2]. Group 1: Transaction Details - The board of directors approved the proposal for the public transfer of 51% equity on August 1, 2025, and the first extraordinary general meeting of shareholders on August 19, 2025 [1]. - The public listing period for this transaction is from August 21, 2025, to August 27, 2025 [1]. - The specific details of the transfer can be found on the Southwest United Property Rights Exchange website [1]. Group 2: Impact on the Company - The transaction is subject to uncertainties regarding the counterparties and final transaction price, which may affect the company's operating performance [2]. - The company emphasizes that the transaction will be conducted based on principles of fairness, openness, and justice, adhering to standardized operational processes and legal disclosure requirements [2].